NetworkNewsBreaks – InMed Pharmaceuticals Inc. (
Post# of 228
InMed Pharmaceuticals (NASDAQ: INM) is a leader in the pharmaceutical research, development, manufacturing and commercialization of rare cannabinoids and cannabinoid analogs. The company today announced that Jerry Griffin, VP of Sales and Marketing for InMed’s subsidiary BayMedica LLC, a leading supplier of bioidentical rare cannabinoids to the health and wellness (“H&W”) market, will be participating in a fireside chat with Water Tower Research on July 25, 2023, at 2:00 p.m. ET. The event is open for all investors with topics that include an overview of BayMedica, its competitive environment and upcoming catalysts, as well as the market dynamics of rare cannabinoids and their disruptive potential in the H&W sector. Interested parties should visit https://nnw.fm/c3DeS to register for the event.
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer